

**Use institution letterhead**

---

Sandra Nusinoff Lehrman M.D.  
Director, Therapeutics Research Program  
Division of AIDS, NIAID, NIH, DHHS  
6700B Rockledge Drive - Room 5101  
Bethesda, MD 20892  
MSC- 7624  
**November 21, 2005**

Dear Dr Lehrman:

Re: Plan for Providing Participant Access to Antiretroviral Drugs after Completion of **PACTG 0004 Insert Protocol Number**

The purpose of this letter is to outline our site's plan to ensure post-trial access to antiretroviral drugs and other HIV care after the completion of **P0004 Insert Protocol Number**. We expect that approximately **X** research subjects will participate in **P0004 Insert Protocol Number** at our site.

We realize that the DAIDS, the PACTG, and the pharmaceutical sponsors will not be responsible for providing medical care or antiretroviral drugs to study subjects after completion of the **P0004 Insert Protocol Number** study.

The post-trial medical care of participants will include general HIV/AIDS clinical care, prophylactic treatment to prevent opportunistic infections, and ongoing access to antiretroviral treatment (ART). **Insert plan for your site, for ex. - this medical care – including ART -- will be available free of charge to participants at the end of the trial through the Botswana Government public sector hospitals and clinics. The Botswana Government has an established and functional National ART Program, and more than 10,000 individuals are already receiving ART through this Government Program in the P0004 study locales.**

We are confident that the **P0004 Insert Protocol Number** study participants at our site will have post-trial treatment access through the above system.

Please let us know if you have any questions.

Yours sincerely,  
**Insert PI name**  
PACTG SITE PI  
**Insert PI Signature**

Cc: NIH: Donna Germuga